A couple in their mid-thirties sits in a sleek clinic, reviewing a price list that looks more like a luxury car brochure. One round of IVF: $20,000. Genetic testing: extra. Egg freezing as a backup plan: extra again. Having a baby — something humans managed for hundreds of thousands of years without invoicing — has become one of the fastest-growing industries on the planet.

This didn't happen overnight. Declining birth rates across wealthy nations, combined with people starting families later and breakthroughs in reproductive science, created a market now worth over $40 billion globally. But behind the hopeful marketing and pastel-colored clinic walls lies a story about class, exploitation, and a future that raises questions we're only beginning to ask.

When Louise Brown was born in 1978 — the world's first "test tube baby" — it felt like science fiction made real. The technology was experimental, controversial, and available to almost nobody. Fast forward to today, and IVF is a mainstream medical procedure. But mainstream doesn't mean accessible. In the United States, a single cycle of IVF costs between $15,000 and $30,000, and most people need multiple cycles. Insurance coverage remains inconsistent at best, nonexistent at worst.

This creates a stark divide. Wealthier couples can pursue round after round of treatment, add genetic screening, freeze embryos, and explore donor options. Meanwhile, working-class families facing the same fertility challenges often have one shot — or none at all. The ability to have a biological child is quietly becoming a luxury good, sorted not by medical need but by income bracket. Countries with universal healthcare, like Denmark or Israel, cover much of the cost. The contrast with the American model is striking.

What makes this particularly uncomfortable is that fertility struggles don't respect tax brackets. Endometriosis, low sperm count, age-related decline — these affect people regardless of wealth. Yet the solution increasingly belongs only to those who can pay. We've created a world where biology is the problem and money is the cure, and if you don't have the money, the problem simply stays.

Takeaway

When the solution to a universal human challenge is priced like a luxury, inequality doesn't just shape what people own — it shapes who gets to become a parent.

In the early 2010s, India was the world's surrogacy capital. Clinics in Gujarat and Mumbai connected wealthy couples from Europe, the U.S., and Australia with Indian women willing to carry pregnancies for a fraction of what it would cost back home. A surrogate in India might earn $5,000 to $8,000 — life-changing money in a rural village, but a tiny sliver of the $100,000 or more the intended parents paid overall. The middlemen and clinic operators kept the difference.

India eventually banned commercial surrogacy for foreigners in 2015, but the industry didn't disappear. It simply migrated — to Ukraine, Cambodia, Kenya, Georgia, and other countries where regulation was light and poverty made recruitment easy. The pattern repeated: vulnerable women in developing nations providing bodily labor for affluent people in wealthier ones. Agencies marketed "affordable surrogacy packages" that included flights, legal support, and accommodation, turning reproduction into something resembling medical tourism.

The ethical knots here are real and tangled. Many surrogates say they entered the arrangement willingly, and the income genuinely transformed their families' prospects. But consent gets complicated when the alternative is deeper poverty. And when contracts dictate what a woman eats, where she lives, and whether she can see her own children during the pregnancy, the word "choice" starts to feel hollow. This is a global supply chain — just one where the product is a human life.

Takeaway

Whenever a market connects the desperation of the poor with the desires of the rich across national borders, calling it a free exchange requires ignoring the gravity that pulls people into it.

In 2018, a Chinese scientist named He Jiankui announced he had edited the genes of twin embryos using CRISPR technology, making them resistant to HIV. The global scientific community reacted with horror — not because the technology didn't work, but because it did, and nobody had agreed on the rules yet. He Jiankui went to prison. But the genie, as they say, was already stretching its legs outside the bottle.

Right now, prospective parents using IVF can screen embryos for serious genetic diseases like cystic fibrosis or Huntington's. That's widely considered ethical. But the same technology inches toward selecting for traits that aren't medical — height, intelligence markers, eye color. Companies already offer "polygenic risk scores" that rank embryos by predicted outcomes. The science is imprecise today. It won't be imprecise forever. And when selection becomes reliable, those who can afford it will face a temptation that no regulation has yet figured out how to contain.

The long-term implication is a potential biological class divide layered on top of the economic one we already have. Imagine a world where wealthy children are not only better educated and better connected, but genetically optimized — healthier, taller, cognitively sharper by design. That's not science fiction anymore. It's a plausible trajectory. And the historical pattern is clear: when powerful new capabilities emerge, access is never evenly distributed. The question isn't whether someone will pursue genetic advantage. It's what happens to everyone else when they do.

Takeaway

Every technology that enhances human capability eventually raises the same question: who gets access first, and does the gap it creates ever close?

The fertility industry didn't emerge from some villainous plot. It grew from genuine human longing — the desire to have children — colliding with biology, economics, and technological possibility. But the structure it's built mirrors the inequalities already running through our world, and in some cases deepens them.

Understanding this history matters because the decisions ahead are enormous. Genetic selection, cross-border surrogacy regulation, and access to reproductive medicine will shape not just individual families but the kind of societies we become. The past doesn't give us answers, but it does show us the patterns — and the patterns suggest we should be paying much closer attention.